Lumping and Splitting: The Need for Precision Medicine and "personomics" in Endometrial Cancer

Overview

Journal J Gynecol Oncol

Specialties Gynecology & Obstetrics
Oncology

Date 2021 Mar 2

PMID 33650339

Citations 3

Authors

Fiorella E Reyes-Baez

Simone Garzon

Andrea Mariani

Affiliations

Soon will be listed here.

Citing Articles

Metastases and Recurrence Risk Factors in Endometrial Cancer-The Role of Selected Molecular Changes, Hormonal Factors, Diagnostic Methods and Surgery Procedures.

Markowska A, Baranowski W, Pitynski K, Chudecka-Glaz A, Markowska J, Sawicki W Cancers (Basel). 2024; 16(1).

PMID: 38201606 PMC: 10778296. DOI: 10.3390/cancers16010179.

Conservative Management of Atypical Endometrial Hyperplasia and Early Endometrial Cancer in Childbearing Age Women.

Uccella S, Zorzato P, Dababou S, Bosco M, Torella M, Braga A Medicina (Kaunas). 2022; 58(9).

PMID: 36143933 PMC: 9504942. DOI: 10.3390/medicina58091256.

Ultrasound Measurement of Tumor-Free Distance from the Serosal Surface as the Alternative to Measuring the Depth of Myometrial Invasion in Predicting Lymph Node Metastases in Endometrial Cancer.

Liro M, Sniadecki M, Wycinka E, Wojtylak S, Brzezinski M, Stanczak A Diagnostics (Basel). 2021; 11(8).

PMID: 34441406 PMC: 8392068. DOI: 10.3390/diagnostics11081472.

References

Wortman B, Creutzberg C, Putter H, Jurgenliemk-Schulz I, Jobsen J, Lutgens L . Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy. Br J Cancer. 2018; 119(9):1067-1074. PMC: 6219495. DOI: 10.1038/s41416-018-0310-8. View

Van den Heerik A, Horeweg N, Nout R, Lutgens L, van der Steen-Banasik E, Westerveld G . PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer. Int J Gynecol Cancer. 2020; 30(12):2002-2007. PMC: 7788476. DOI: 10.1136/ijgc-2020-001929. View

Bosse T, Peters E, Creutzberg C, Jurgenliemk-Schulz I, Jobsen J, Mens J . Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer. 2015; 51(13):1742-50. DOI: 10.1016/j.ejca.2015.05.015. View

Ziegelstein R . Personomics. JAMA Intern Med. 2015; 175(6):888-9. DOI: 10.1001/jamainternmed.2015.0861. View

Mariani A, Webb M, Keeney G, Haddock M, Calori G, Podratz K . Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?. Am J Obstet Gynecol. 2000; 182(6):1506-19. DOI: 10.1067/mob.2000.107335. View

Mariani A, Webb M, Keeney G, Lesnick T, Podratz K . Surgical stage I endometrial cancer: predictors of distant failure and death. Gynecol Oncol. 2002; 87(3):274-80. DOI: 10.1006/gyno.2002.6836. View

Mariani A, Sebo T, Webb M, Riehle D, Katzmann J, Keeney G . Molecular and histopathologic predictors of distant failure in endometrial cancer. Cancer Detect Prev. 2003; 27(6):434-41. DOI: 10.1016/j.cdp.2003.09.005. View

Tuomi T, Pasanen A, Leminen A, Butzow R, Loukovaara M . Prediction of lymphatic dissemination in endometrioid endometrial cancer: Comparison of three risk-stratification models in a single-institution cohort. Gynecol Oncol. 2017; 144(3):510-514. DOI: 10.1016/j.ygyno.2017.01.003. View

Chang S, Lee T . Beyond Evidence-Based Medicine. N Engl J Med. 2018; 379(21):1983-1985. DOI: 10.1056/NEJMp1806984. View

10.

Mokhles S, Takkenberg J, Treasure T . Evidence-Based and Personalized Medicine. It's [AND] not [OR]. Ann Thorac Surg. 2016; 103(1):351-360. DOI: 10.1016/j.athoracsur.2016.08.100. View

11.

Tortorella L, Restaino S, Zannoni G, Vizzielli G, Chiantera V, Cappuccio S . Substantial lymph-vascular space invasion (LVSI) as predictor of distant relapse and poor prognosis in low-risk early-stage endometrial cancer. J Gynecol Oncol. 2021; 32(2):e11. PMC: 7930448. DOI: 10.3802/jgo.2021.32.e11. View

12.

Milam M, Java J, Walker J, Metzinger D, Parker L, Coleman R . Nodal metastasis risk in endometrioid endometrial cancer. Obstet Gynecol. 2012; 119(2 Pt 1):286-92. PMC: 3266531. DOI: 10.1097/AOG.0b013e318240de51. View

13.

Blackstone E . Precision Medicine Versus Evidence-Based Medicine: Individual Treatment Effect Versus Average Treatment Effect. Circulation. 2019; 140(15):1236-1238. DOI: 10.1161/CIRCULATIONAHA.119.043014. View

14.

Ramirez P, Frumovitz M, Pareja R, Lopez A, Vieira M, Ribeiro R . Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. N Engl J Med. 2018; 379(20):1895-1904. DOI: 10.1056/NEJMoa1806395. View

15.

Mariani A, Webb M, Keeney G, Aletti G, Podratz K . Predictors of lymphatic failure in endometrial cancer. Gynecol Oncol. 2002; 84(3):437-42. DOI: 10.1006/gyno.2001.6550. View

16.

Hunter D, Longo D . The Precision of Evidence Needed to Practice "Precision Medicine". N Engl J Med. 2019; 380(25):2472-2474. DOI: 10.1056/NEJMe1906088. View

17.

Morrow C, Bundy B, Kurman R, Creasman W, Heller P, Homesley H . Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991; 40(1):55-65. DOI: 10.1016/0090-8258(91)90086-k. View

18.

Marnitz S, Walter T, Schomig-Markiefka B, Engler T, Kommoss S, Brucker S . A Modern Approach to Endometrial Carcinoma: Will Molecular Classification Improve Precision Medicine in the Future?. Cancers (Basel). 2020; 12(9). PMC: 7564776. DOI: 10.3390/cancers12092577. View

19.

AlHilli M, Mariani A, Bakkum-Gamez J, Dowdy S, Weaver A, Peethambaram P . Risk-scoring models for individualized prediction of overall survival in low-grade and high-grade endometrial cancer. Gynecol Oncol. 2014; 133(3):485-93. PMC: 4405150. DOI: 10.1016/j.ygyno.2014.03.567. View

20.

Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Ledermann J . ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol. 2015; 27(1):16-41. DOI: 10.1093/annonc/mdv484. View